Trial Profile
Safety, Tolerance and preliminary Efficacy of nasal administration of NASVAC therapeutic vaccine candidate in chronic hepatitis B patients- A phase I, open, not controlled clinical trial.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs ABX 203 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record.
- 14 Sep 2011 New trial record